STYK1 and lung carcinoma: Targets such as Nrf2 (Lou et al., 2021; Takahashi et al., 2020; Wang et al., 2023), LSH (Ho and Crabtree, 2010; Mao et al., 2018; Jiang et al., 2017; Wang et al., 2019a), STYK1/NOK (Ma et al., 2019; Lai et al., 2019), and ACSL4 (Doll et al., 2017; Kuwata and Hara, 2019; Hou et al., 2022) also hold significant promise in the field of ferroptosis in lung cancer.